NASDAQ · Biotechnology

Orchard Therapeutics plc (ORTX) Stock

$16.70 +0.30% NASDAQ: ORTX Healthcare

Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing gene-based treatments for severe and often fatal rare conditions, operating across the United Kingdom, European Union, and the United States. Their innovative gene therapy strategy involves modifying a patient's own hematopoietic stem cells, converting them into a therapeutic cellular drug that can address the illness with just one dose.

Valuation

MetricValue
Price$16.70
Market Cap$380.11M
P/E Ratio-27.38
P/B Ratio2.17
P/S Ratio54.41
EPS (TTM)$-0.61
52-Week High$16.72
52-Week Low$4.24
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-5.12%
ROA-3.60%
ROCE-19.95%
Gross Margin65.17%
Operating Margin-452.22%
Net Margin-112.84%
Debt/Equity0.59
Current Ratio2.78

Annual Financials (USD)

Metric20182019202020212022
Revenue$2.0M$3.0M$3.0M$0$7.0M
Operating Profit$-235.0M$-173.0M$-157.0M$-36.0M$-32.0M
Net Profit$-230.0M$-163.0M$-152.0M$-36.0M$-8.0M
EPS$-102.17$-17.53$-15.28$-2.93$-0.61
Op Margin-11321.3%-6879.1%-6049.3%-7539.3%-452.2%

Balance Sheet (USD)

Metric20182019202020212022
Total Assets$366.0M$399.0M$281.0M$322.0M$219.0M
Total Liabilities$55.0M$100.0M$103.0M$112.0M$121.0M
Cash$336.0M$19.0M$55.0M$56.0M$68.0M
Borrowings$0$46.0M$58.0M$59.0M$58.0M

Latest News

Lawyer says substance found after fatal Houston ICE shooting was salt USA TODAY · Jul 17, 2026 Market Chatter: UK's Burnham Said He Plans North Sea Drilling, Thames Water Nationalization MT Newswires · Jul 17, 2026 3 Reasons to Sell DECK and 1 Stock to Buy Instead StockStory · Jul 17, 2026 UGG's cozy bedding set is on rare sale for $70 at Macy's TheStreet · Jul 17, 2026 Columbia Financial, Inc. Announces the Results of Its Offering; Final Merger Consideration; and Anticipated Closing Date GlobeNewswire · Jul 17, 2026

Cash Flow (USD)

Metric20182019202020212022
Operating Cash Flow$-98.0M$-166.0M$-126.0M$-125.0M$-76.0M
Investing Cash Flow$-8.0M$-314.0M$145.0M$-35.0M$84.0M
Financing Cash Flow$355.0M$157.0M$4.0M$158.0M$-1.0M
Net Cash Flow$250.0M$-316.0M$36.0M$1.0M$12.0M
Free Cash Flow$-102.0M$-170.0M$-139.0M$-128.0M$-83.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-45.77
FCF Yield-21.70%
Quick Ratio2.72
Interest Coverage-33.86
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CKPTCheckpoint Therapeutics, Inc. $4.26 +0.00% -3.00 $367.72M 0.00%
CLYM $14.00 +0.00% -11.77 $801.68M 0.00%
CTEVClaritev Corporation $21.73 +0.56% -1.25 $370.45M 0.00%
GTHXG1 Therapeutics, Inc. $7.16 +0.14% -7.70 $377.75M 0.00%
ITOSiTeos Therapeutics, Inc. $10.15 +0.20% -3.89 $448.68M 0.00%

About Orchard Therapeutics plc

Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing gene-based treatments for severe and often fatal rare conditions, operating across the United Kingdom, European Union, and the United States. Their innovative gene therapy strategy involves modifying a patient's own hematopoietic stem cells, converting them into a therapeutic cellular drug that can address the illness with just one dose. The company markets Strimvelis, a gammaretroviral therapy approved for treating adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Orchard's clinical pipeline features several investigational therapies, including OTL-101 for ADA-SCID, OTL-200 targeting metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Early-stage research programs encompass OTL-203 for mucopolysaccharidosis type I, OTL-201 for MPS-IIIA, and OTL-202 for MPS IIIB. Furthermore, a strategic partnership with Pharming Group N.V. covers the research, development, production, and commercialization of OTL-105, an experimental ex vivo autologous hematopoietic stem cell gene therapy designed for hereditary angioedema. Established in 2015 as Orchard Rx Limited, Orchard Therapeutics plc is headquartered in London, UK.

Orchard Therapeutics plc is headquartered in GB.

Orchard Therapeutics plc (ORTX) stock trades at $16.70 with a market capitalization of $380.11M. The stock is valued at a price-to-earnings (P/E) ratio of -27.38, price-to-book of 2.17, price-to-sales of 54.41. Over the past 52 weeks the stock has ranged between $4.24 and $16.72, and currently trades at its 52-week high.

On profitability, Orchard Therapeutics plc generates a return on equity (ROE) of -5.12%, return on capital employed of -19.95%, an operating margin of -452.22%, a net profit margin of -112.84%.

Official website: www.orchard-tx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides